

**RECEIVED**

JUL 10 2001

TECH CENTER 1600/2900

#8

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICECERTIFICATE OF MAILING

I hereby certify that this RESPONSE and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Donald G. Lewis
Donald G. Lewis

June 19, 2001
Date of Deposit

Applicant: Lee, et al.)
Serial No.: 09/581,044) Group Art Unit: 1653
Filed: June 8, 2000) Examiner: J. Russel
Title: HIV/FIV PROTEASE INHIBITORS)
HAVING A SMALL P3 RESIDUE) Our Ref.: TSRI 609.1

**RESPONSE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES (37 CFR §1.821-1.825)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the PTO Action including a request to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825 mailed December 19, 2000, enclosed is a Sequence Listing on paper copy, made in accordance with 37 CFR §1.821 - §1.825. No Notice to Comply was enclosed in the PTO Action. Also enclosed is the Sequence Listing in computer readable form, submitted as required by 37 CFR §1.821(e), on which the Sequence Listing is labeled OPT0020P.txt.

Applicants respectfully request entry of the Sequence Listing and computer readable copy thereof.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(a) through (c) and (e), respectively, are the same and include no new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that making willful false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

June 19, 2001
Date

Donald G. Lewis
Donald G. Lewis, Reg. No. 28,636

THE SCRIPPS RESEARCH INSTITUTE
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, California 92037
(858) 784-2937